Which medications in the drug class Complete Regimen Combinations are used in the treatment of HIV Infection and AIDS?

Updated: Jul 01, 2019
  • Author: Nicholas John Bennett, MBBCh, PhD, MA(Cantab), FAAP; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print
Answer

Complete Regimen Combinations

Complete fixed-dose regimens assist with medication adherence. Two-, three-, and four-drug combination products are available to decrease pill burden and administration frequency.

Dolutegravir/rilpivirine (Juluca)

First 2-drug, fixed-dose combination complete regimen approved for HIV infection. It is indicated for adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) and on a stable ART regimen for ≥ 6 months with no history of treatment failure and no known substitutions associated with resistance to dolutegravir or rilpivirine.

Dolutegravir/lamivudine (Dovato)

First 2-drug, fixed-dose, complete regimen for treatment-naïve adults with HIV-1 infection with no known substitutions associated with resistance to dolutegravir or lamivudine. Combines integrase strand transfer inhibitor (INSTI) plus nucleoside reverse transcriptase inhibitor (NRTI). 

Elvitegravir/cobicistat/emtricitabine/tenofovir AF (Genvoya)

Antiretroviral combination product that provides a complete, once-daily regimen for treatment-naïve adults and adolescents aged ≥ 12 y, or to replace the current ART regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable ART regimen for at least 6 months with no history of treatment failure. Each tablet contains an integrase inhibitor (elvitegravir 150 mg) and 2 NRTIs (emtricitabine 200 mg and tenofovir AF 10 mg). It also contains cobicistat, a CYP3A4 inhibitor used as a booster for elvitegravir, a CYP3A4 substrate.

Darunavir/cobicistat/emtricitabine/tenofovir AF (Symtuza)

Complete regimen indicated for treatment of HIV-1 infection in adults who have no prior antiretroviral (ART) treatment history or who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable ART regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir.

Emtricitabine/rilpivirine/tenofovir AF (Odefsey)

Antiretroviral combination product that provides a complete, once-daily regimen for treatment-naïve adults and adolescents aged ≥ 12 y, or to replace the current ART regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable ART regimen for at least 6 months with no history of treatment failure. Each tablet contains 1 NNRTI (rilpivirine 25 mg) and 2 NRTIs (emtricitabine 200 mg and tenofovir AF 25 mg).

Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Stribild)

Antiretroviral combination product that provides a complete, once-daily regimen for treatment-naïve adults. Contains an integrase inhibitor and 2 NRTIs plus cobicistat, a CYP3A4 inhibitor used as a booster for elvitegravir, a CYP3A4 substrate. Cobicistat enhances the systemic exposure of CYP3A substrates, such as elvitegravir, where bioavailability is limited and half-life is shortened by CYP3A-dependent metabolism.

Emtricitabine/rilpivirine/tenofovir DF (Complera)

Complete regimen combination consisting of 2 NRTIs and 1 NNRTI. It is indicated for treatment of HIV-1 infection in patients aged ≥ 12 years with no antiretroviral treatment history and with HIV-1 RNA ≤ 100,000 copies/mL at the start of therapy, and in certain virologically-suppressed (HIV-1 RNA < 50 copies/mL) patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen.

Bictegravir/emtricitabine/tenofovir AF (Biktarvy)

Three-drug combination of bictegravir (BIC), an HIV-1 integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs). Indicated as a complete regimen for treatment of HIV-1 infection in adults and pediatric patients weighing ≥25 kg who are ART-naïve or replacement of current antiretroviral regimen in patients who are virologically suppressed (HIV-1 RNA

Efavirenz/lamivudine/tenofovir DF (Symfi, Symfi Lo)

Three-drug combination of a non-nucleoside reverse transcriptase inhibitor, and two nucleo(t)side reverse transcriptase inhibitors and is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and children who weigh at least 35 kg (Symfi Lo) and 40 kg (Symfi).

Doravirine/lamivudine/tenofovir DF (Delstrigo)

Indicated as a complete, once daily, regimen for treatment of HIV-1 infection in adults without prior antiretroviral therapy (ART) treatment history.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!